Vaccinex presents pepinemab AD/HD data at AAIC 2022; SIGNAL-AD first patient completed with no safety concerns

VACCINEX, INC.

Presented poster at AAIC 2022 on pepinemab (SEMA4D antibody) for Alzheimer's and Huntington's disease.
Phase 2 HD study showed pepinemab restored learning and increased brain metabolic activity (FDG-PET).
Ongoing Phase 1/2a SIGNAL-AD study: first patient completed with no safety concerns as of Q2 2022.
Pepinemab targets glial activation to reduce neuroinflammation; funded by Alzheimer's Association and ADDF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.